A Study of Epoetin Beta (NeoRecormon) in Participants With Solid Tumors

An Open-Label Study of the Safety Of NeoRecormon in Patients With Solid Tumors Being Treated With Platinum Capable of Inducing Anemia

This study will evaluate the safety of subcutaneous (SC) epoetin beta (NeoRecormon) in adults with solid tumors being treated with platinum-based chemotherapy capable of inducing anemia. The anticipated time on study treatment is 16 weeks, and the target sample size is approximately 208 individuals.

Inclusion Criteria:

• Adults at least 18 years of age
• Presence of solid tumor(s)
• Receiving platinum-based therapy capable of inducing anemia

Exclusion Criteria:

• Red blood cell transfusion within 7 days prior to study drug
• Relevant acute or chronic bleeding requiring therapy within 3 months prior to study drug
• Women who are pregnant or breastfeeding